Special conference on tumor immunology and immunotherapy

A new chapter

Katelyn T. Byrne, Robert H. Vonderheide, Elizabeth Jaffee, Todd D Armstrong

Research output: Contribution to journalArticle

Abstract

The overall objective of the fifth American Association for Cancer Research Special Conference, "Tumor Immunology and Immunotherapy: A New Chapter," organized by the Cancer Immunology Working Group, was to highlight multidisciplinary approaches of immunotherapy and mechanisms related to the ability of immunotherapy to fight established tumors. With the FDA approval of sipuleucel-T, ipilimumab (anti-CTLA-4; Bristol-Myers Squibb), and the two anti-PD-1 antibodies, pembrolizumab (formerly MK-3475 or lambrolizumab; Merck) and nivolumab (Bristol-Myers Squibb), immunotherapy has become a mainstream treatment option for some cancers. Many of the data presented at the conference and reviewed in this article showcase the progress made in determining the mechanistic reasons for the success of some treatments and the mechanisms associated with tolerance within the tumor microenvironment, both of which are potential targets for immunotherapy. In addition to combination and multimodal therapies, improvements in existing therapies will be needed to overcome the numerous ways that tumorspecific tolerance thwarts the immune system. This conference built upon the success of the 2012 conference and focused on seven progressing and/or emerging areas-new combination therapies, combination therapies and vaccine improvement, mechanisms of antibody therapy, factors in the tumor microenvironment affecting the immune response, the microbiomes effect on cancer and immunotherapy, metabolism in immunotherapy, and adoptive T-cell therapy.

Original languageEnglish (US)
Pages (from-to)590-597
Number of pages8
JournalCancer immunology research
Volume3
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Allergy and Immunology
Immunotherapy
Neoplasms
Tumor Microenvironment
Therapeutics
Combined Vaccines
Adoptive Immunotherapy
Antibodies
Microbiota
Cell- and Tissue-Based Therapy
Immune System
T-Lymphocytes
pembrolizumab

ASJC Scopus subject areas

  • Cancer Research
  • Immunology

Cite this

Special conference on tumor immunology and immunotherapy : A new chapter. / Byrne, Katelyn T.; Vonderheide, Robert H.; Jaffee, Elizabeth; Armstrong, Todd D.

In: Cancer immunology research, Vol. 3, No. 6, 01.06.2015, p. 590-597.

Research output: Contribution to journalArticle

@article{55843f47872546f0a4af1a90a243d683,
title = "Special conference on tumor immunology and immunotherapy: A new chapter",
abstract = "The overall objective of the fifth American Association for Cancer Research Special Conference, {"}Tumor Immunology and Immunotherapy: A New Chapter,{"} organized by the Cancer Immunology Working Group, was to highlight multidisciplinary approaches of immunotherapy and mechanisms related to the ability of immunotherapy to fight established tumors. With the FDA approval of sipuleucel-T, ipilimumab (anti-CTLA-4; Bristol-Myers Squibb), and the two anti-PD-1 antibodies, pembrolizumab (formerly MK-3475 or lambrolizumab; Merck) and nivolumab (Bristol-Myers Squibb), immunotherapy has become a mainstream treatment option for some cancers. Many of the data presented at the conference and reviewed in this article showcase the progress made in determining the mechanistic reasons for the success of some treatments and the mechanisms associated with tolerance within the tumor microenvironment, both of which are potential targets for immunotherapy. In addition to combination and multimodal therapies, improvements in existing therapies will be needed to overcome the numerous ways that tumorspecific tolerance thwarts the immune system. This conference built upon the success of the 2012 conference and focused on seven progressing and/or emerging areas-new combination therapies, combination therapies and vaccine improvement, mechanisms of antibody therapy, factors in the tumor microenvironment affecting the immune response, the microbiomes effect on cancer and immunotherapy, metabolism in immunotherapy, and adoptive T-cell therapy.",
author = "Byrne, {Katelyn T.} and Vonderheide, {Robert H.} and Elizabeth Jaffee and Armstrong, {Todd D}",
year = "2015",
month = "6",
day = "1",
doi = "10.1158/2326-6066.CIR-15-0106",
language = "English (US)",
volume = "3",
pages = "590--597",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Special conference on tumor immunology and immunotherapy

T2 - A new chapter

AU - Byrne, Katelyn T.

AU - Vonderheide, Robert H.

AU - Jaffee, Elizabeth

AU - Armstrong, Todd D

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The overall objective of the fifth American Association for Cancer Research Special Conference, "Tumor Immunology and Immunotherapy: A New Chapter," organized by the Cancer Immunology Working Group, was to highlight multidisciplinary approaches of immunotherapy and mechanisms related to the ability of immunotherapy to fight established tumors. With the FDA approval of sipuleucel-T, ipilimumab (anti-CTLA-4; Bristol-Myers Squibb), and the two anti-PD-1 antibodies, pembrolizumab (formerly MK-3475 or lambrolizumab; Merck) and nivolumab (Bristol-Myers Squibb), immunotherapy has become a mainstream treatment option for some cancers. Many of the data presented at the conference and reviewed in this article showcase the progress made in determining the mechanistic reasons for the success of some treatments and the mechanisms associated with tolerance within the tumor microenvironment, both of which are potential targets for immunotherapy. In addition to combination and multimodal therapies, improvements in existing therapies will be needed to overcome the numerous ways that tumorspecific tolerance thwarts the immune system. This conference built upon the success of the 2012 conference and focused on seven progressing and/or emerging areas-new combination therapies, combination therapies and vaccine improvement, mechanisms of antibody therapy, factors in the tumor microenvironment affecting the immune response, the microbiomes effect on cancer and immunotherapy, metabolism in immunotherapy, and adoptive T-cell therapy.

AB - The overall objective of the fifth American Association for Cancer Research Special Conference, "Tumor Immunology and Immunotherapy: A New Chapter," organized by the Cancer Immunology Working Group, was to highlight multidisciplinary approaches of immunotherapy and mechanisms related to the ability of immunotherapy to fight established tumors. With the FDA approval of sipuleucel-T, ipilimumab (anti-CTLA-4; Bristol-Myers Squibb), and the two anti-PD-1 antibodies, pembrolizumab (formerly MK-3475 or lambrolizumab; Merck) and nivolumab (Bristol-Myers Squibb), immunotherapy has become a mainstream treatment option for some cancers. Many of the data presented at the conference and reviewed in this article showcase the progress made in determining the mechanistic reasons for the success of some treatments and the mechanisms associated with tolerance within the tumor microenvironment, both of which are potential targets for immunotherapy. In addition to combination and multimodal therapies, improvements in existing therapies will be needed to overcome the numerous ways that tumorspecific tolerance thwarts the immune system. This conference built upon the success of the 2012 conference and focused on seven progressing and/or emerging areas-new combination therapies, combination therapies and vaccine improvement, mechanisms of antibody therapy, factors in the tumor microenvironment affecting the immune response, the microbiomes effect on cancer and immunotherapy, metabolism in immunotherapy, and adoptive T-cell therapy.

UR - http://www.scopus.com/inward/record.url?scp=84961875160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961875160&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-15-0106

DO - 10.1158/2326-6066.CIR-15-0106

M3 - Article

VL - 3

SP - 590

EP - 597

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 6

ER -